BioMedNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Added to PMLS Menu of Testing Services

Premier Medical Laboratory Services (“PMLS”), a nation-leading advanced medical diagnostics lab, today announced that it has added Aditxt’s (NASDAQ: ADTX) AditxtScore(TM) to its menu of testing services. AditxtScore provides more clarity regarding a patient’s individual immunity profile and allows patients to know their level of protection that an immune response to the virus or vaccination has provided them. “As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” said Kevin Murdock, CEO of Premier Medical Laboratory Services. “With AditxtScore, individuals can make more informed decisions about whether vaccination, boosters or other risk mitigation strategies are the right course of action for them.”

To view the full press release, visit https://ibn.fm/L7U9z

About Aditxt Inc.

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork